Atrial Natriuretic Peptide (ANP), Rat: Core Mechanisms & Research Utility

Executive Summary: Atrial Natriuretic Peptide (ANP), rat, is a 28-amino acid peptide hormone produced by atrial myocytes in response to hemodynamic and neurohumoral stimuli (APExBIO, A1009). ANP is a potent vasodilator and regulator of sodium, water, and adipose tissue homeostasis (see review). Its mechanism involves activation of guanylyl cyclase-linked receptors, leading to cGMP signaling cascades. ANP lowers blood pressure by increasing renal sodium excretion and directly relaxing vascular smooth muscle. Experimental solutions are stable at ≥122.5 mg/mL in DMSO or ≥43.5 mg/mL in water at -20°C, with purity confirmed by HPLC and mass spectrometry (95.92%).

Biological Rationale

Atrial Natriuretic Peptide (ANP) is synthesized, stored, and secreted by atrial myocytes in the heart. Release is triggered by atrial distension, angiotensin II, endothelin, and sympathetic nervous system activation. ANP acts systemically to regulate blood volume, electrolyte balance, and metabolic homeostasis (contrast: focuses on actionable workflows). In rodents, ANP is fundamental for maintaining normotension and preventing volume overload. It also modulates adipose tissue metabolism, influencing lipid mobilization and energy balance (see: integrative mechanisms).

Mechanism of Action of Atrial Natriuretic Peptide (ANP), rat

ANP binds to natriuretic peptide receptor-A (NPR-A), a guanylyl cyclase-linked receptor predominantly expressed in vascular and renal tissues. This activates intracellular cGMP synthesis, which mediates smooth muscle relaxation and inhibits sodium reabsorption in renal collecting ducts. ANP antagonizes the renin-angiotensin-aldosterone system (RAAS), suppresses renin and aldosterone secretion, and enhances natriuresis and diuresis. In adipose tissue, ANP stimulates lipolysis via cGMP-dependent protein kinase pathways. The peptide’s sequence (H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH) is essential for full receptor activation and biological activity (update: advanced protocol guidance).

Evidence & Benchmarks

• ANP induces potent vasodilation and reduces mean arterial pressure in rat models within minutes of administration (Zhang et al., 2022).
• ANP injection at pharmacological doses increases urinary sodium excretion (natriuresis) and urine output in Sprague Dawley rats (Zhang et al., Table 2).
• ANP inhibits renin and aldosterone secretion, contributing to RAAS suppression and blood pressure homeostasis (APExBIO, A1009).
• ANP modulates adipose tissue metabolism by activating cGMP-mediated lipolysis (Vasonatrin-Peptide, 2023).
• Purity of >95% (HPLC/MS) and solubility of ≥122.5 mg/mL in DMSO or ≥43.5 mg/mL in water enable reproducible assay results (APExBIO, A1009).

Applications, Limits & Misconceptions

ANP is widely applied in cardiovascular, renal, and metabolic research. It is a reference standard for studies on hypertension, congestive heart failure, and natriuresis mechanisms. In cell-based assays, ANP enhances assay reproducibility by delivering highly defined molecular activity (contrast: focuses on assay troubleshooting). Recent research also explores its role in adipose tissue metabolism regulation and translational models of metabolic syndrome.

Common Pitfalls or Misconceptions

• ANP is ineffective in models lacking functional NPR-A receptor expression.
• Long-term storage of ANP solutions leads to degradation; always prepare fresh aliquots for each experiment.
• ANP is insoluble in ethanol; attempts to dissolve in ethanol will result in precipitation and loss of activity.
• Not all commercially available lots match the >95% purity and validated sequence of the APExBIO A1009 product.
• ANP does not substitute for BNP or CNP in signaling or physiologic assays; receptor specificity is critical.

Workflow Integration & Parameters

For experimental use, the solid peptide should be dissolved in DMSO (≥122.5 mg/mL) or water (≥43.5 mg/mL) at room temperature. Solutions are stable for short-term use only and should be stored at -20°C. Avoid freeze-thaw cycles. The product is supplied with a molecular formula of C49H84N20O15S and a molecular weight of 1225.38 Da. All preparations should be confirmed for purity by HPLC or MS prior to use. The recommended workflow is detailed on the Atrial Natriuretic Peptide (ANP), rat product page. For protocol optimization and troubleshooting, see BNP1-32.com (focuses on cell assay reproducibility).

Conclusion & Outlook

Rat Atrial Natriuretic Peptide (ANP) is a validated, high-purity research tool for cardiovascular, renal, and metabolic investigations. Its defined mechanism, rapid onset of action, and robust solubility profile make it indispensable for blood pressure homeostasis and natriuresis studies. APExBIO’s A1009 product offers benchmark purity and reliability, supporting reproducibility in translational research. Future directions include expanded use in metabolic syndrome models and combinatorial studies with other natriuretic peptides.